Predicting kidney and liver damage in cancer patients receiving chemotherapy

化疗是使用化学物质治疗疾病，通常用于治疗癌症。化疗通常是细胞毒性的，两种常见的风险与肾脏和肝脏损害有关。受影响的患者可能需要延迟或更改治疗，甚至暂停治疗。虽然只有10%的患者会遇到肾和/或肝损伤，但目前的最佳实践要求对所有患者进行定期血液检测。目前还没有办法对个别患者的风险进行分层。**该项目的愿景是准确预测接受化疗的患者的肾脏和肝脏损害的风险**。这一预测的结果将意味着低风险患者可以省去不必要的医院验血和监测，而高风险患者可以得到更适当的治疗。到目前为止，达勒姆大学的计算机科学家与伦敦大学学院医院(UCLH)的药剂师密切合作，开发了一种机器学习算法，可以准确预测肝肾功能。结果已经在许多关键会议和利益相关者活动上分享，临床上对将该算法应用于临床实践有着强烈的兴趣。**该项目的主要重点领域将是一项前瞻性的诊断准确性研究**。这将产生一个商业概念验证(POC)软件应用程序，它将允许由达勒姆大学学者生产的经过验证的算法用于现场临床实践。主要目标将包括：*开发POC软件，以允许在现场临床环境中测试算法*快速迭代开发POC，以实现商业启动*数据收集到验证算法*识别第三方软件接口机会(特别是化疗电子处方系统)*开发商业化计划目前在英国，每年约有375,000名患者被诊断为癌症，其中约28%的患者预计将因其原发病接受化疗[[1]][0]。由于西方世界的癌症发病率相似，这项创新可能会为全球数百万人提供个性化的护理。Https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence[0]：#_ftn1[1]：#_ftnref1

Chemotherapy is the treatment of disease using chemical substances, commonly used to treat cancer.Chemotherapy is often cytotoxic and two common risks relate to kidney and liver damage. Affected patients may require delays or changes to treatment and even treatment suspension.Whilst only <10% of patients will encounter kidney and or liver damage, current best practice requires monitoring for all patients with regular blood testing. There is currently no way to stratify risk in individual patients.**The vision for this project is to accurately predict the risk of kidney and liver damage in patients receiving chemotherapy**. The result of this prediction will mean low risk patients can be saved unnecessary trips to hospital for blood tests and monitoring whilst high risk patients can receive more appropriate management.To date, computer scientists at Durham University, working closely with pharmacists at University College London Hospital (UCLH) have developed a machine learning algorithm to accurately predict liver and kidney function.Results have been shared at a number of key conferences and stakeholder events and there is strong clinical interest in utilising this algorithm in clinical practice.**The main area of focus for this project will be a prospective diagnostic accuracy study**. This will produce a commercial proof-of-concept (POC) software application that will allow the validated algorithm, produced by Durham University academics, to be used in live clinical practice.Key objectives will include:* Develop POC software to allow algorithm to be tested in a live clinical setting* Rapid iterative development of POC to enable commercial launch* Data collection to validation algorithm* Identification of third-party software interface opportunities (particularly chemotherapy e-prescribing systems)* Development of commercialisation planCurrently ~375k patients are diagnosed with cancer every year in the UK, with ~28% of these expected to receive chemotherapy for their primary disease[[1]][0].With similar rates of cancer incidence across the Western world, this innovation could personalise care for millions globally. https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence[0]: #_ftn1[1]: #_ftnref1